aTyr Pharma (LIFE) Tops Q4 EPS by 22c

aTyr Pharma (NASDAQ: LIFE) reported Q4 EPS of ($0.26), $0.22 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $10.4 thousand versus the consensus estimate of $416.67 thousand.

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.

You May Also Be Interested In

• Ethos Technologies mentioned cautiously at Hunterbrook
• BofA Securities Reiterates Underperform Rating on HubSpot Inc (HUBS)
• Jana Partners urges Cooper Companies to replace CEO and explore asset sales